Evidence Tier: Phase 1-2 Clinical Data — GHRP-2 (pralmorelin) is a synthetic hexapeptide GH secretagogue that acts on the ghrelin receptor. Approved in Japan as a diagnostic agent for GH deficiency.
Overview
GHRP-2 (D-Ala-D-betaNal-Ala-Trp-D-Phe-Lys-NH2) is one of the earliest synthetic growth hormone releasing peptides. It is a potent agonist of the GHS-R1a receptor and has been approved in Japan under the name pralmorelin for diagnostic use in GH deficiency assessment.
Compared to Other GHRPs
Unlike Ipamorelin, GHRP-2 can elevate cortisol and prolactin at higher doses. It also stimulates appetite through ghrelin receptor activation. GHRP-6 has stronger appetite effects than GHRP-2.
References
- Bowers CY. "Growth hormone-releasing peptide (GHRP)." Cell Mol Life Sci. 1998;54(12):1316-1329.
Research Disclaimer
This article is compiled from peer-reviewed research and publicly available scientific literature. It is intended for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health-related decisions.